Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

BURLINGTON, N.C.--( BUSINESS WIRE )--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Thomas (Tom) Pike will join Labcorp as president and chief executive officer of its Drug Development Clinical Development business unit on Jan. 9, 2023. Until the planned spin-off of the Clinical Development business, which is expected to occur in mid-2023, Mr. Pike will report to Labcorp's chairman and CEO Adam Schechter. At the time of the spin-off, Mr. Pike will serve as the chief executive officer and chairman of the Board of the independent, publicly listed company. In the coming months, Labcorp will announce the Board of Directors of the new company, including its lead independent director.

Thomas Pike to Join Labcorp as President and Chief Executive Officer of Its Drug Development Clinical Development Business Unit

BURLINGTON, N.C.--( BUSINESS WIRE )--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10 at 4:30 p.m. (PT).

Labcorp to Speak at the 41st Annual J.P. Morgan Healthcare Conference

LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to help match patients with critical and potentially life-changing treatments for cancer and other diseases.

LabCorp (LH) Gains on Innovation Amid Currency Headwinds

Bruker

GREENVILLE S.C.--( BUSINESS WIRE )--Kiyatec Inc. announced today a closing of its Series C funding round totaling US$18 million from new and existing investors. New investor Bruker (Nasdaq: BRKR) led the financing and was joined by existing investors Seae Ventures, VentureSouth, and LabCorp (NYSE: LH). Use of funds will focus on accelerating adoption of the company's commercially available clinical testing and preclinical pharma services, which add value across the life cycle of successful cancer drugs.

Functional precision oncology leader Kiyatec announces Series C round with US$18 million closing to accelerate adoption of transformational cancer platform

LabCorp's (LH) new laboratory is likely to advance clinical trials across therapeutic areas like oncology, hemato-oncology and liver diseases.

LabCorp's (LH) New APH Lab to Expand Global Capabilities

BURLINGTON, N.C.--( BUSINESS WIRE )--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has begun operations at a new, larger anatomic pathology and histology (APH) laboratory in Los Angeles, expanding the company's global central laboratory capabilities.

Labcorp Opens New Los Angeles Based Laboratory

Cerner's lab information systems selected to help Labcorp streamline operations and enhance patient experiences for a leading health system  KANSAS CITY, Mo. , Nov. 14, 2022 /PRNewswire/ -- Oracle Cerner and Labcorp, a leading global life sciences company, have formed a new relationship to streamline lab operations for one of the nation's leading nonprofit Catholic health systems.

Oracle Cerner Technology to Manage Hospital Labs in 10 States

LabCorp continues to rate as a buy following its Q3 numbers, despite a large pullback in Covid-19 revenue. Offsetting the distribution to its top-line, LH continues to compound capital and return on equity in the double digits, with debt flat YoY.

Laboratory Corporation: Buy Rating Holds Following Solid Mid-Level Growth

Labcorp to Speak at the Credit Suisse 31st Annual Healthcare Conference

No investor likes when their company trims its guidance.

Why Labcorp Stock Sank by Almost 6% on Thursday

Laboratory Corporation of America Holdings (NYSE:LH ) Q3 2022 Earnings Conference Call October 27, 2022 9:00 AM ET Company Participants Chas Cook - VP, IR Adam Schechter - President, CEO & Chairman Glenn Eisenberg - CFO & EVP Conference Call Participants Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Patrick Donnelly - Citigroup Eric Coldwell - Robert W. Baird & Co. A.J.

Laboratory Corporation of America Holdings (LH) Q3 2022 Earnings Call Transcript

LabCorp's (LH) organic revenues decline significantly, mainly due to major decrease in COVID-19 PCR and antibody testing sales.

LabCorp (LH) Misses Q3 Earnings Estimates, Updates Guidance

LabCorp (LH) delivered earnings and revenue surprises of -0.64% and 5.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Q3 Earnings and Revenues Miss Estimates

Shares of Labcorp LH, +0.76% tumbled 4.7% in premarket trading on Thursday after the diagnostics company said revenue in the third quarter of 2022 came in lower than expected as fewer people got PCR or antigen tests for COVID-19. Labcorp had earnings of $352.8 million, or $3.90 per share, in the third quarter of 2022, down from $587.3 million, or $6.05 per share, in the same quarter a year ago.

Labcorp's stock falls 4% after COVID-19 test sales decline in the third quarter

Labcorp Announces 2022 Third Quarter Results

Ironwood Pharma

U.S. market indexes rose on Thursday morning as investors were encouraged by several key earnings reports and Treasury yields continued to climb.

2 Health Care Stocks That Fit Graham's Lost Formula

Labcorp Appoints Google Cloud Executive Kirsten Kliphouse to Its Board of Directors

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced the completion of transactions that establish a long-term laboratory relationship with Ascension, one of the leading non-profit and Catholic health systems in the United States. “Today's announcement marks the beginning of an exciting chapter for both organizations, and for the patients, communities and clinicians we serve,” said Dr. Brian Caveney, chief medical officer and president o

Labcorp Establishes Comprehensive Laboratory Relationship With Ascension

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, will release its financial results for the third quarter of 2022 before the market opens on Thursday, Oct. 27, 2022. The company will host a conference call and webcast beginning at 9 a.m. ET that day to discuss the results. The earnings press release and accompanying financial information will be posted on the Labcorp Investor Relations website. The call will be webcast live on the Labcorp Investor R

Labcorp to Announce Third Quarter Financial Results on October 27, 2022

Amazon

Alexandria Real Estate Equities

Bath and Body Works

Salesforce

Catalent

Caesars Entertainment

Alphabet

IQVIA Hlds

Microsoft

ServiceNow

Teradyne

Wall Street analysts follow S&P 500 stocks more closely than almost anyone. But even they get it wrong sometimes, too.

Analysts Totally Blow It On 12 Gutsy Stock Recommendations

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that members of the executive management team will participate in a fireside chat at the Baird 2022 Global Healthcare Conference on Tuesday, Sept. 13, at 9:05 a.m. ET. A live webcast of the fireside chat will be available via the Labcorp Investor Relations website and archived for replay. About Labcorp Labcorp is a leading global life sciences company that provides vital information to

Labcorp to Speak at the Baird 2022 Global Healthcare Conference

BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of RWJBarnabas Health's outreach laboratory business and select related assets. RWJBarnabas Health is New Jersey's largest academic health system. “The communities, physicians and health systems we serve are central to everything we do at Labcorp,” said Bill Haas, senior vice president of Labcorp Diagnostic's Northeast Division. “Our expanded relation

Labcorp Acquires Clinical Outreach Laboratory Services From RWJBarnabas Health

LabCorp announced that it is pursuing a tax-free spinoff of its Drug Development segment. The transaction will separate a slower-growing, highly profitable cash cow from a high growth business, allowing investors to realize significant value.

LabCorp: Drug Development Segment Spinoff Poised To Generate Significant Value

Labcorp is a well-run company that should benefit from long-term secular trends in the healthcare industry. It benefits from its large patient database, which aids its drug development services business for large pharmaceutical companies.

Laboratory Corp: The Force Is Strong With This One

AbbVie

AmerisourceBergen

Bristol-Myers

Quest Diagnostics

HCA Healthcare

McKesson

Merck

Pfizer

Viatris

The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet.

News for Labcorp Holdings Inc Stock (LH)